Kuculmez Ozlem
Altern Ther Health Med. 2025 Jan;31(1):10-14.
Fibromyalgia is a musculoskeletal disease that is frequently detected in young women, includes symptoms such as fatigue, sleep disturbances, and cognitive dysfunction unrelated to pain, and negatively affects the patient's quality of daily life. Ozone therapy increases tissue oxygenation, activates antioxidant mechanisms, and may be used in patients with fibromyalgia. The aim of this study is to investigate the efficacy of ozone therapy on pain and functional status in fibromyalgia patients.
It was a longitudinal cross-sectional study. The study was performed by Baskent University Alanya Hospital. Patients, aged between 20 and 65 years, diagnosed with fibromyalgia according to American College of Rheumatology 2010 criteria and had ozone therapy were included to the study. It was hypothesized that the ozonetherapy increases tissue oxygenization, decreases pain level and supplies better quality of life in patients with fibromyalgia. Demographic and three-month follow-up data of fibromyalgia patients who had received 10 sessions of ozone autohemotherapy were obtained from the hospital database. The patients received 10 sessions of ozone autohemotherapy at a concentration of 25 µg/ml (100 ml of blood and 100 ml of ozone gas) 2-3 times per week. The values of the Visual Analog Score and Fibromyalgia Impairment Questionnaire scores in the three-month follow-up were statistically compared, and P < .05 was considered statistically significant.
20 female patients were analyzed. The mean age of patients was 54. 8 ± 15. 5 years. Patients' median (min-max) baseline score on Visual Analog Score was 9 (5-10), post-treatment score was 3 (0-8), 3 (1-8) in 1st month, and 4 (1-8) in 3rd month. The median (min-max) Fibromyalgia Impairment Questionnaire score of patients was 73.29 (29.2 - 87.2) at baseline, 31.67 (7.01 - 66.99) after treatment, 24. 6 (10. 7- 63. 3) at 1st month, and 24.67 (10.67- 66.99) 3rd month. A significant decrease in pain (P < .001) and functional improvement (P < .001) was observed in the patients after ozonetherapy.
After 10 sessions of ozonetherapy in fibromyalgia patients, the Visual Analog Score and Fibromyalgia Impairment Questionnaire scores decreased significantly and this well-being persisted for three months. Ozonetherapy may be considered for fibromyalgia treatment protocol as complementary therapy. For determining dosage and session standarts further studies are needed.
纤维肌痛是一种在年轻女性中经常被检测出的肌肉骨骼疾病,其症状包括疲劳、睡眠障碍以及与疼痛无关的认知功能障碍,对患者的日常生活质量产生负面影响。臭氧疗法可增加组织氧合、激活抗氧化机制,可用于纤维肌痛患者。本研究的目的是调查臭氧疗法对纤维肌痛患者疼痛和功能状态的疗效。
这是一项纵向横断面研究。该研究由巴斯肯大学阿拉尼亚医院进行。年龄在20至65岁之间、根据美国风湿病学会2010年标准被诊断为纤维肌痛且接受了臭氧疗法的患者被纳入该研究。假设臭氧疗法可增加纤维肌痛患者的组织氧合、降低疼痛水平并提供更好的生活质量。从医院数据库中获取接受了10次臭氧自血疗法的纤维肌痛患者的人口统计学数据和三个月随访数据。患者每周接受2至3次浓度为25μg/ml(100ml血液和100ml臭氧气体)的10次臭氧自血疗法。对三个月随访中的视觉模拟评分和纤维肌痛损害问卷评分值进行统计学比较,P <.05被认为具有统计学意义。
对20名女性患者进行了分析。患者的平均年龄为54.8±15.5岁。患者视觉模拟评分的中位数(最小值 - 最大值)基线评分为9(5 - 10),治疗后评分为3(0 - 8),第1个月为3(1 - 8),第3个月为4(1 - 8)。患者纤维肌痛损害问卷评分的中位数(最小值 - 最大值)在基线时为73.29(29.2 - 87.2),治疗后为31.67(7.01 - 66.99),第1个月为24.6(10.7 - 63.3),第3个月为24.67(10.67 - 66.99)。臭氧疗法后患者的疼痛显著减轻(P <.001)且功能得到改善(P <.001)。
纤维肌痛患者接受10次臭氧疗法后,视觉模拟评分和纤维肌痛损害问卷评分显著降低,且这种良好状态持续了三个月。臭氧疗法可作为辅助疗法被考虑纳入纤维肌痛治疗方案。为确定剂量和疗程标准,还需要进一步研究。